Healthcare Industry News: Alzheimer’s disease
News Release - April 22, 2008
Resolvyx Pharmaceuticals Strengthens Its Board of Directors with Industry LeadersBEDFORD, Mass.--(HSMN NewsFeed)--Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the appointment of Timothy J. Barberich and George M. Milne, Jr., Ph.D, to Resolvyx’s Board of Directors. Resolvyx is focused on developing drugs based on resolvins, a recently discovered family of naturally-occurring, small molecule lipid mediators that actively resolve inflammation and can be targeted to treat a wide range of diseases, including asthma, cardiovascular disease and multiple eye diseases.
A founder of Sepracor, Inc., Timothy J. Barberich is currently Chairman of the Board of Sepracor and was the company's Chief Executive Officer from inception in 1984 to 2007. Prior to founding Sepracor, Mr. Barberich served in a number of executive and managerial capacities at Millipore Corporation, which he joined in 1973. Mr. Barberich also serves as a director of BioSphere Medical, Inc., Gemin X Biotechnologies, and serves as a trustee of Boston Medical Center.
George M. Milne, Jr., Ph.D. is a venture partner of Radius Ventures LLC. From 1993 to 2000, Dr. Milne served as President of Central Research for Pfizer, Inc. and oversaw both human and veterinary research and development. Following Pfizer's merger with Warner Lambert, he held the position of Executive Vice President of Global Research and Development and also served as President of Strategic and Operations Management. Dr. Milne serves on the board of directors of several publicly-traded companies including Charles River Laboratories, Inc., Mettler-Toledo, Inc., and, Athersys, Inc., as well as several emerging companies including BioStorage Technologies, Inc., Rib-X Pharmaceuticals, Inc., and Sensorin, Inc.
“Resolvyx is delighted to welcome Tim and George to our Board of Directors. They both bring a wealth of experience in innovation, clinical and product development, and commercial strategy to our team”, said Paul Rubin, M.D., Resolvyx’s President and Chief Executive Officer. “As Resolvyx rapidly advances multiple compounds to and through the clinic, we will greatly benefit from our Board’s strengths in leading our efforts to fulfill the breakthrough therapeutic potential of resolvins to address unmet patient needs.”
Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, resolvins act to protect healthy tissue during an immuno-inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the environmental insult has passed. Resolvins have shown highly potent efficacy in pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others.
Resolvins are attractive drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis. Such diseases include auto-immune diseases (like Crohn’s disease, psoriasis and rheumatoid arthritis), allergic diseases (like asthma) and chronic inflammatory disease (like atherosclerosis, degenerative retinal diseases, chronic dry eye and Alzheimer’s disease). Resolvins offer an entirely novel biological approach to treating significant inflammatory diseases, with a decreased potential for immuno-suppression.
About Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Resolvyx's drug R&D programs are focused on characterizing and developing resolvin-based compounds. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive portfolio of more than 55 patents and applications. The company's headquarters are in Bedford, Massachusetts.
For additional information, please visit www.resolvyx.com.
Source: Resolvyx Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.